These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 10454971)

  • 1. Cost-effective treatment of acute coronary syndromes-IIB or not IIB?
    Klein WW
    Eur Heart J; 1999 Sep; 20(17):1217-9. PubMed ID: 10454971
    [No Abstract]   [Full Text] [Related]  

  • 2. Economic assessment of tirofiban in the management of acute coronary syndromes in the hospital setting: an analysis based on the PRISM PLUS trial.
    Szucs TD; Meyer BJ; Kiowski W
    Eur Heart J; 1999 Sep; 20(17):1253-60. PubMed ID: 10454977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet glycoprotein IIb/IIIa receptor blockade in unstable coronary disease.
    Chesebro JH; Badimon JJ
    N Engl J Med; 1998 May; 338(21):1539-41. PubMed ID: 9593795
    [No Abstract]   [Full Text] [Related]  

  • 4. National economic impact of tirofiban for unstable angina and myocardial infarction without ST elevation; example from the United Kingdom.
    Bakhai A; Flather MD; Collinson JR; Stevens W; Normand C; Alemao E; Itzler R; Ben-Joseph R
    Int J Cardiol; 2003 Oct; 91(2-3):163-72. PubMed ID: 14559126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TACTICS-TIMI 18 shows positive results of invasive approach.
    Cardiovasc J S Afr; 2001; 12(1):58-9. PubMed ID: 11474693
    [No Abstract]   [Full Text] [Related]  

  • 6. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
    Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators
    N Engl J Med; 1998 May; 338(21):1488-97. PubMed ID: 9599103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tirofiban in unstable coronary disease.
    Liron M
    N Engl J Med; 1998 Oct; 339(16):1163-5. PubMed ID: 9776651
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).
    Huynh T; Theroux P; Snapinn S; Wan Y;
    Am Heart J; 2003 Oct; 146(4):668-73. PubMed ID: 14564321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes.
    Boersma E
    J Am Coll Cardiol; 2007 Jan; 49(2):276; author reply 277. PubMed ID: 17222743
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis.
    Glaser R; Glick HA; Herrmann HC; Kimmel SE
    J Am Coll Cardiol; 2006 Feb; 47(3):529-37. PubMed ID: 16458131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GP IIb/IIIa inhibitors: an evidence-based approach to their use.
    Med Manag Netw; 1999 Mar; 7(3):5-9. PubMed ID: 10346546
    [No Abstract]   [Full Text] [Related]  

  • 12. [Costs and cost-effectiveness of Eptifibatide in the treatment of coronary ischemic syndromes. An analysis based on the PURSUIT study].
    Szucs TD; Schwenkglenks M; Berger K; Karsch K
    Z Kardiol; 2003 Mar; 92(3):236-44. PubMed ID: 12658471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cost effectiveness of clopidogrel in acute coronary syndromes without ST-elevation (unstable angina, non-Q AMI)].
    Hagymási K
    Orv Hetil; 2004 Jun; 145(23):1251-2. PubMed ID: 15323070
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
    Cannon CP; Weintraub WS; Demopoulos LA; Vicari R; Frey MJ; Lakkis N; Neumann FJ; Robertson DH; DeLucca PT; DiBattiste PM; Gibson CM; Braunwald E;
    N Engl J Med; 2001 Jun; 344(25):1879-87. PubMed ID: 11419424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of low-molecular-weight heparin and glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Fernandez JS; Sadaniantz A
    Med Health R I; 2001 Feb; 84(2):37-43. PubMed ID: 11272658
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction.
    Okmen E; Cakmak M; Tartan Z; Cam N
    Heart Vessels; 2003 Jul; 18(3):117-22. PubMed ID: 12955426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Super-aspirins in severe angina.
    Harv Heart Lett; 1998 Dec; 9(4):1-3. PubMed ID: 9925977
    [No Abstract]   [Full Text] [Related]  

  • 18. Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy).
    Gibson CM; Singh KP; Murphy SA; DiBattiste PM; Demopoulos LA; Cannon CP; Braunwald E;
    Am J Cardiol; 2004 Aug; 94(4):492-4. PubMed ID: 15325937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes.
    Plosker GL; Ibbotson T
    Pharmacoeconomics; 2003; 21(12):885-912. PubMed ID: 12908844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes.
    Campbell P
    N Engl J Med; 2001 Nov; 345(21):1573-4; author reply 1574-5. PubMed ID: 11794228
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.